@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix proteinModification: . @prefix psimod: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:11892; a Protein: . sub:_2 belv:variantOf hgnc:6871; a proteinModification:, psimod:00696 . sub:_3 occursIn: obo:CLO_0001601, species:9606; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(HGNC:TNF) -> p(HGNC:MAPK1,pmod(P,T,185))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "20131211" . sub:_4 prov:value "The TNF-a-stimulated phosphorylation of ERK1/2 kinases was robust at 15 min (Fig. 7A, lane 2) but returned to basal levels thereafter. As shown in Fig. 7B, treatment of cells with the ERK inhibitor PD98059 completely blocked TNF-a-stimulated ERK1/2 activation."; prov:wasQuotedFrom pubmed:17082637 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:17082637; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:06.365+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }